Frontier Capital Management Co. LLC purchased a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 298,052 shares of the company's stock, valued at approximately $7,022,000. Frontier Capital Management Co. LLC owned about 0.29% of Dyne Therapeutics at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. abrdn plc acquired a new stake in Dyne Therapeutics during the fourth quarter worth about $608,000. Raymond James Financial Inc. purchased a new stake in Dyne Therapeutics during the fourth quarter worth approximately $2,340,000. Barclays PLC grew its stake in Dyne Therapeutics by 162.2% during the third quarter. Barclays PLC now owns 207,309 shares of the company's stock worth $7,446,000 after buying an additional 128,246 shares during the period. Schroder Investment Management Group increased its position in shares of Dyne Therapeutics by 63.3% in the fourth quarter. Schroder Investment Management Group now owns 147,002 shares of the company's stock worth $3,477,000 after acquiring an additional 56,961 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in shares of Dyne Therapeutics by 54.5% during the 4th quarter. Wells Fargo & Company MN now owns 38,754 shares of the company's stock valued at $913,000 after acquiring an additional 13,677 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.
Analyst Ratings Changes
Several equities analysts recently commented on the company. Guggenheim reissued a "buy" rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. Piper Sandler decreased their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating for the company in a research note on Friday, February 28th. Chardan Capital reaffirmed a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a research note on Friday. Royal Bank of Canada reissued an "outperform" rating and issued a $45.00 price objective on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Finally, JPMorgan Chase & Co. reduced their target price on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a research note on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $46.85.
Check Out Our Latest Report on Dyne Therapeutics
Insider Buying and Selling at Dyne Therapeutics
In related news, insider Oxana Beskrovnaya sold 2,598 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the transaction, the insider now owns 199,087 shares of the company's stock, valued at $2,777,263.65. This trade represents a 1.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders have sold 6,237 shares of company stock valued at $77,760. Company insiders own 14.14% of the company's stock.
Dyne Therapeutics Price Performance
DYN stock traded down $0.46 on Tuesday, reaching $12.10. The company's stock had a trading volume of 2,915,615 shares, compared to its average volume of 1,667,890. Dyne Therapeutics, Inc. has a 52 week low of $6.36 and a 52 week high of $47.45. The company has a market capitalization of $1.37 billion, a P/E ratio of -3.40 and a beta of 1.19. The firm has a fifty day moving average of $10.38 and a two-hundred day moving average of $17.85.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.17). As a group, equities analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.
About Dyne Therapeutics
(
Free Report)
Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
See Also
Before you consider Dyne Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dyne Therapeutics wasn't on the list.
While Dyne Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
